drugset / Trial / NCT00781378

Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China

NCT00781378 ↗

Phase 4 Completed 118 enrolled Beijing Chao Yang Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Recombinant tissue plasminogen activator (rt-PA) is currently the most commonly used thrombolytic drug in patients with pulmonary thromboembolism (PTE). Optimal dosing with maximal benefits and minimal risks is of great importance. Considering the lower body weight in general Chinese population, we compared the efficacy and safety of lower dose rt-PA 50mg/2h regimen with the FDA-approved rt-PA 100mg/2h regimen in selected PTE patients.

Timeline

Start
2002-06
Primary completion
2006-02
Completion
2006-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant tissue plasminogen activator Protein / enzyme biologic 50 mg Intravenous
Subject Recombinant tissue plasminogen activator Protein / enzyme biologic 100 mg Intravenous